• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Schafer Joshua increased direct ownership by 98,033% to 210,004 units (SEC Form 5)

    2/6/25 7:34:27 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SHPH alert in real time by email
    SEC FORM 5/A SEC Form 5
    FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0362
    Estimated average burden
    hours per response: 1.0
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Form 3 Holdings Reported.
    X
    Form 4 Transactions Reported.
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Schafer Joshua

    (Last) (First) (Middle)
    C/O SHUTTLE PHARMACEUTICALS HOLDINGS
    401 PROFESSIONAL DRIVE, SUITE 260

    (Street)
    GAITHERSBURG, MD 20879

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
    12/31/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    02/03/2025
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Amount (A) or (D) Price
    Common Stock 12/23/2024 A4 209,790(1) A $0 210,004(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents 209,790 restricted stock units ("RSUs") issued to the Reporting Person under the Shuttle Pharmaceuticals Holdings, Inc. 2018 Equity Incentive Plan. The 209,790 RSUs which are scheduled to vest in one third increments on each of 12/31/2025, 12/31/2026 and 12/31/2027.
    2. Consists of (1) 214 shares of common stock and (2) 209,790 RSUs which remain subject to vesting.
    Remarks:
    This Form 5/A is being filed to correct the transaction date on the Reporting Person's February 3, 2025 Form 5 filing.
    /s/ Joshua Schafer 02/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SHPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SHPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SHPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

      GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Heal

      6/4/25 4:01:00 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shuttle Pharma Provides Corporate Update

      GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update. Shuttle Pharma's recent highlights: Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma highlights include: Patient enrollment nears milestone as nearly 50% enrollment has been achieved in the initial randomized portion of the trial.84% of the enrolled patients have completed all seven cycles.Ropidoxuridine is being reported as we

      5/15/25 4:45:00 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

      GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that it has nearly achieved 50% enrollment in the initial randomized portion of its Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma, with treatment sites reporting that the drug has been well tolerated and toxicity no greater than 2 on a scale of 1-5. Further, 84% of the enrolled patients have completed all seven cycles. Shuttle has begun anal

      5/8/25 4:01:00 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SHPH
    SEC Filings

    See more
    • Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

      5/15/25 4:25:17 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Shuttle Pharmaceuticals Holdings Inc.

      SCHEDULE 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

      5/15/25 3:53:02 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.

      10-Q - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

      5/8/25 5:29:46 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SHPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Cooper Chris

      3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

      4/2/25 8:00:25 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Nabyt Oleh claimed ownership of 184,162 shares (SEC Form 3)

      3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

      3/21/25 8:00:04 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Scorsis George claimed ownership of 184,162 shares (SEC Form 3)

      3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

      3/21/25 8:00:07 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SHPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Shuttle Pharmaceuticals Holdings Inc. (Amendment)

      SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

      10/17/23 6:57:47 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Shuttle Pharmaceuticals Holdings Inc.

      SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

      5/30/23 5:30:57 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SHPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

      GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Heal

      6/4/25 4:01:00 PM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

      GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities. "I am excited to welcome Christopher Cooper as Co-CEO of

      3/12/25 6:20:00 AM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

      GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Timothy Lorber, CPA, as the Company Chief Financial Officer. The Company's current Chief Financial Officer, Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and will assume the Vice President, Regulatory position on a full-time basis. Mr. Lorber is a CPA with more than 40 years of profession

      6/18/24 9:00:00 AM ET
      $SHPH
      Biotechnology: Pharmaceutical Preparations
      Health Care